Actemra Access: Roche Open To Partnering Patent Pools
Executive Summary
Roche is open to considering tie-ups with the Medicines Patent Pool or other voluntary patent pools to assess partners for Actemra, as part of efforts to broaden access to the immunotherapy for COVID-19. With a patent non-assert declaration on tocilizumab already in place, activists say the geographic scope of patent licenses will need to be broadened to have any real impact.
You may also be interested in...
MPP’s Guide To Cutting Biosimilar Approval Times, Costs By Third Or More
The Medicines Patent Pool has conducted a study on the impact of licensing and technology transfer on the timeline and costs of developing five biosimilars, including Merck’s Keytruda. While a licensing deal for pembrolizumab might not be a near-term possibility, the findings could help licensors, licensees and regulators increase access to medicines.
MPP's Guide To Cutting Biosimilar Approval Times, Costs By Third Or More
The Medicines Patent Pool has conducted a study on the impact of licensing and technology transfer on the timeline and costs of developing five biosimilars, including Merck’s Keytruda. While a licensing deal for pembrolizumab might not be a near-term possibility, the findings could help licensors, licensees and regulators increase access to medicines.
COVID-19-Induced Actemra Shortage Causes Headaches For CAR-T Centers
While some cancer centers report sufficient stocks of the drug, they have already been turning to potential alternatives due to supply issues that could last for weeks or months.